Latest News

Tuesday, November 07, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Phase 3/4 Trials, Product Launches and Updates

Oral Vimpat Approved for Use in Pediatric Patients with Partial-Onset Seizures

The FDA approved a label extension for Vimpat (lacosamide, UCB) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years and older. The expanded ind…

Read the full story

Friday, October 27, 2017 | Clinical Trials, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Biogen

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disea…

Read the full story

Friday, October 27, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Merck & Co. H

ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS

Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the proportion of patients with …

Read the full story

Friday, October 27, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications

ECTRIMS: Alkermes Demontrates Safety and GI Tolerability of Investigational Oral Agent for Relapsing MS

Alkermes presented safety and gastrointestinal (GI) tolerability data from EVOLVE-MS-1, an ongoing open-label, two-year phase 3 safety study for ALKS 8700, a novel, oral monomethyl fumarate (MMF) prod…

Read the full story

Friday, October 27, 2017 | Healthcare Trends, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

ECTRIMS: Genentech Data Signals Emphasis on Multiple Sclerosis Disease Progression, Disability

Data presented by Genentech at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- Americas Committee for Treatment and Research in Multiple Sclerosis (ACT…

Read the full story

Tuesday, October 24, 2017 | Concussion & Brain Injury, Personnel/Company News

Neural Analytics Partners with Department of Defense to Develop Portable Device to Assess Combat-Related TBI

The Department of Defense (DoD) has awarded Neural Analytics, Inc. a $10 million contract to develop and supply a portable, point-of-injury device for assessing combat-related traumatic brain inj…

Read the full story

Tuesday, October 24, 2017 | Dementia & Cognitive Disorders, FDA Approval/Clearance, Phase 3/4 Trials, Research and Publications

FDA Fast-Tracks Alzheon’s Anti-Amyloid Alzheimer’s Agent

The FDA has granted Fast Track designation to Alzheon, Inc.’s investigational anti-amyloid drug ALZ-801 for the treatment of Alzheimer’s disease (AD). Using a precision medicine approach, …

Read the full story

Friday, October 20, 2017 | Multiple Sclerosis & Immune Disorders, Research and Publications

Corrona Partners with National MS Society on Registry to Assess Safety and Efficacy of Therapies

Corrona, LLC and the National Multiple Sclerosis Society will collaborate on the launch of the Corrona Multiple Sclerosis (MS) Registry to study the comparative safety and effectiveness of approved MS…

Read the full story

Thursday, October 19, 2017 | Product Launches and Updates, Research and Publications

Phenogenetic Database For Stem Cell Models of Neurological Diseases Launched

Based on the results of a novel meta-analysis of all induced pluripotent stem cells, researchers have created an atlas of how cell characteristic in neurological and neurodegenerative diseases are lin…

Read the full story

Wednesday, October 18, 2017 | Concussion & Brain Injury, Research and Publications

National Grant Awarded to Mount Sinai to Continue the New York Traumatic Brain Injury Model System

The National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR) has awarded the Icahn School of Medicine at Mount Sinai’s Department of Rehabilitation Medicine and…

Read the full story

Thursday, October 12, 2017 | FDA Approval/Clearance, Headache & Pain, Phase 3/4 Trials, Research and Publications, Pfizer

Once-Daily Lyrica Formulation Wins FDA Approval

The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and t…

Read the full story

Monday, October 09, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Next-Generation VNS System and Implantable Device Approved

LivaNova has received FDA approval for its next-generation Vagus Nerve Stimulation (VNS) Therapy Programming System for drug-resistant epilepsy. The FDA has also approved the company's SenTiv…

Read the full story

Wednesday, October 04, 2017 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Product Launches and Updates

FDA Greenlights Two Generic Glatiramer Acetate Formulations for Relapsing MS

The FDA approved Mylan’s generic versions of glatiramer acetate, including a three-times weekly 40mg/mL formulation of glatiramer acetate and a once-daily 20mg/mL formulation…

Read the full story

Monday, October 02, 2017 | Dementia & Cognitive Disorders

US Postal Service Issues Alzheimer’s Disease Semipostal Stamps

New stamps for Alzheimer’s disease awareness are coming soon from the US Postal Service. Under its semipostal discretionary program, the Postal Service will issue five stamps over a 10-year peri…

Read the full story

Friday, September 29, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

Investigational Low-Dose Fenfluramine Shows Promise in Phase 3 Trial for Dravet Syndrome

Phase 3 findings suggest that the investigational ZX008 (low-dose fenfluramine hydrochloride, Zogenix) is effective for the treatment of Dravet syndrome. The study enrolled 119 patients across sites i…

Read the full story
Load More